丘脑胶质瘤综合治疗疗效分析  

An Analysis of the Rosponse of Comprehensive Treatment for Thalamic Glioma

作　　者：蒋静[1] 房彤[1] 陈力[1] 孙保锦[1] 宋丽楠[1] 候栋梁[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院,北京100038

出　　处：《中国肿瘤》2014年第1期68-71,共4页China Cancer

摘　　要：[目的]分析丘脑胶质瘤病例综合治疗的治疗结果。[方法]2009年6月至2011年12川收治病理确诊的匠脑胶质瘤患者3l例，接受手术近全切除10例，部分切除14例，活检术7例？术后调强放射治疗8例，三维适形放射治疗23例；1．8～2．0Gy／次，总剂量48．6～60．0Gv（中位剂量54Gy）。放疗期间同步口服替莫唑胺化疗20例。中位随访35．4个月。[结果]全组患者中位生存时间20．6个月，l、2、3年总生存率分别为74．2％、45．2％和36．2％。多因素分析显示WHO分级低、放疗同步化疗的患者预后较好。[结论]WHO分级和放疗期间同步替莫唑胺化疗是影响丘脑胶质瘤预后的主要因素，手术在丘脑胶质瘤治疗中的地位有待进一步研究。[Purpose] To investigate the therapic results of comprehensive treatment for thalamic glioma. [ Methods ] From Jun.2009 to Dec.2011,31 cases pathological proven with WHO grade 11-1V： thalamic giioma were eligible for the analysis. Of the 31 cases, 10 cases accepted subtotal resection, 14 cases,partial resection ;and 7,biopsy;8 cases,intensity-modulated radiation therapy （IMRT） and 23 cases,three dimensional radiotherapy（3DCRT） with 1.8-2.0Gy/f, total dose（DT） 48.6-60.0Gy,and median DT 54Gy.Twenty cases aceepted concurrent chemoradiotherapy of temozolomide. The median tbllow-up was 35.4 months.[Results] Of all patients,the median survival was 20.6 months,and the 1-, 2- aud 3-year overall survival rate was 74.2%,45.2% and 36.2% respectively. Multivariate analysis showed that the patients with lower WHO grade and concurrent chemotherapy of temozolomide gave a better survival.[Conclusion ] WHO grade and concurrent chemotherapy of temozolomide is the main faclor aftcting fire thalamic gliomas prognosis. The effects of operation need to be further studied.

关 键 词：丘脑肿瘤 外科学 放射疗法 化学疗法 

分 类 号：R739.41[医药卫生—肿瘤]